Human Saphenous Vein Ex Vivo Culture as a Translational Model of Intimal Hyperplasia
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
BACKGROUND
Intimal hyperplasia (IH) significantly limits the long-term patency of saphenous vein grafts following bypass surgery, with no human models available to fully understand its complex pathogenesis. Although animal models, primarily murine systems, have provided mechanistic insights into IH, limitations persist in translating these findings to human pathophysiology. Here, we evaluate the translational value of a static ex vivo culture model using human saphenous vein segments to study IH.
METHODS
Human saphenous vein segments obtained from patients who underwent lower limb bypass surgery were cultured ex vivo for 7 days under static conditions. Histological and immunohistochemical analyses were conducted to evaluate endothelial dysfunction, vascular smooth muscle cell (VSMC) phenotype switching, extracellular matrix (ECM) remodeling, inflammation, and apoptosis. Spatial transcriptomics (GeoMx) were employed to characterize the localized transcriptional alterations, which were subsequently validated using targeted qPCR, western blotting, and additional immunostaining techniques.
RESULTS
Cultured vein segments developed characteristic features of IH, including marked endothelial dysfunction, increased apoptosis and proliferation, ECM remodeling and neointima formation. Spatial transcriptomics revealed localized VSMC dedifferentiation and activation of inflammatory, oxidative stress, and ECM remodeling pathways. Importantly, we also observed evidence of osteochondrogenic differentiation of human VSMCs during IH, with significant upregulation of osteogenic markers such as RunX2.
CONCLUSIONS
Our ex vivo human saphenous vein model captures the complex molecular and cellular dynamics of IH, offering insights into endothelial dysfunction, VSMC plasticity, and osteochondrogenic transitions. This translational model holds significant promise for evaluating novel therapeutic strategies targeting graft IH.
